# SANA — slm-full-cpu

## Metadata

ticker: SANA
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: d9deb227ba88122ea5ee4be12210cd839c6be895b555fb1469ce7d14904ad620
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 548, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 171.935, "latency_s_total": 171.935, "parse_failure": 0, "prompt_tokens": 2059, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 411, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 154.797, "latency_s_total": 154.797, "parse_failure": 0, "prompt_tokens": 2048, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 145, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 47.075, "latency_s_total": 47.075, "parse_failure": 0, "prompt_tokens": 601, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 136, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 39.773, "latency_s_total": 39.773, "parse_failure": 0, "prompt_tokens": 595, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 180, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 57.813, "latency_s_total": 57.813, "parse_failure": 0, "prompt_tokens": 485, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 143, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 67.137, "latency_s_total": 67.137, "parse_failure": 0, "prompt_tokens": 630, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 930, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 144.824, "latency_s_total": 144.824, "parse_failure": 0, "prompt_tokens": 1590, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "SANA",
  "company_name": "Sana Biotechnology, Inc.",
  "current_price": 2.88,
  "currency": "USD",
  "market_cap": 862158656.0,
  "forward_pe": -5.1881614,
  "week_52_high": 6.55,
  "week_52_low": 2.61,
  "financial_currency": "USD",
  "net_income": -211822000.0,
  "profit_margin_pct": 0.0,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-03",
    "summary": "Item 1A. Ris k Factors. Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Annual Report, including our financial statements and related notes included elsewhere in this Annual Report, before making an investment decision. The risks described below are not the only ones we face. Many of the following risks and uncertainties are, and will continue to be, exacerbated by any worsening of the global geo-political, business, and economic environment. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect o"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-10",
    "summary": "Item 1A. Ri sk Factors Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Quarterly Report, including our financial statements and related notes included elsewhere in this Quarterly Report, before making an investment decision. The risks described below are not the only ones we face. Many of the following risks and uncertainties are, and will continue to be, exacerbated by any worsening of the global geo-political, business, and economic environment. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely aff"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the SEC EDGAR filing for ticker SANA, the key takeaways regarding risk factors and business outlook include:

**1. Unproven Technology and Development Risks**
*   The company’s *ex vivo* and *in vivo* cell engineering platforms rely on novel technologies that are unproven and may not result in approvable or marketable products.
*   There are no FDA-approved therapeutics derived from pluripotent stem cells (PSCs) or utilizing the company’s fusogen technology.
*   Scientific evidence supporting these platforms is preliminary, limited, and ongoing. Preclinical and clinical testing is inherently unpredictable, and results from animal models or preclinical cell lines may not accurately predict safety and efficacy in humans.
*   The company has not tested its platforms on all cell types or microenvironments, and results may not translate across different contexts.

**2. Regulatory and Safety Challenges**
*   The company faces difficulties in creating appropriate models and assays to evaluate the safety and purity of its product candidates.
*   There is a risk that regulatory authorities may not be satisfied with the data provided to explain unexpected results observed during testing.
*   Manufacturing reagents and materials may have unknown or unanticipated effects on safety, efficacy, or manufacturability, potentially affecting multiple programs and causing delays.

**3. Financial and Operational Uncertainties**
*   There is substantial doubt as to the company’s ability to continue as a going concern.
*   The company requires additional funding to finance operations. Failure to raise capital when needed could force the delay, reduction, or elimination of product development programs or commercialization efforts.
*   If the company fails to successfully identify, develop, and commercialize product candidates, or experiences significant delays, its business, financial condition, and results of operations will be materially adversely affected.

**4. Strategic and Personnel Dependencies**
*   The company may not realize the benefits of acquired, in-licensed, or future technologies, nor may it successfully enter into or benefit from strategic relationships.
*   Future growth and the development of cell engineering platforms depend heavily on retaining key personnel and recruiting additional qualified staff.
*   Managing growth, particularly in development and regulatory capabilities, may lead to operational disruptions.

**5. Forward-Looking Statements**
*   Statements regarding future events are based on current expectations and estimates but are subject to significant uncertainties.
*   Actual results may differ materially from those expressed or implied by forward-looking statements due to various risk factors, including those not currently known or deemed immaterial.
*   The company does not undertake an obligation to publicly update these statements.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Unproven Technology:** The company’s ex vivo and in vivo cell engineering platforms are based on novel technologies that are unproven and may not result in approvable or marketable products. There is substantial doubt regarding the feasibility of developing therapeutic treatments based on these platforms, as scientific evidence is preliminary and limited.
*   **Development Uncertainty:** Preclinical and clinical testing is inherently unpredictable. Results from animal models or preclinical assays may not accurately predict safety and efficacy in humans, and results from one cell type or microenvironment may not translate to others.
*   **Regulatory and Safety Challenges:** The company may encounter significant challenges in creating appropriate models and assays to evaluate safety and purity. There is a risk that unexpected results in testing may not be satisfactorily explained to regulatory authorities, potentially leading to delays or rejection.
*   **Product Candidate Variability:** Product candidates may reveal unexpected differences in safety or efficacy when developed for different indications or compared to other candidates using the same technologies, potentially requiring changes to manufacturing or clinical plans.
*   **Commercialization and Financial Risks:** If the company fails to successfully identify, develop, and commercialize product candidates, or experiences significant delays, its business and financial condition will be materially adversely affected. There is substantial doubt as to the company’s ability to continue as a going concern, and it requires additional funding to finance operations. Failure to raise capital could force the company to delay, reduce, or eliminate development programs.
*   **Strategic and Operational Risks:** The company may not realize the benefits of acquired or in-licensed technologies or strategic relationships. Its growth depends on retaining key personnel and recruiting qualified staff. Additionally, the company may encounter difficulties in managing growth, which could disrupt operations.
*   **Forward-Looking Statement Risks:** Actual results may differ materially from forward-looking statements due to significant uncertainties, new risk factors, and incomplete information. The company undertakes no obligation to update these statements.

## Pre-written sections (judge input)

### Financial Health

Sana Biotechnology, Inc. (SANA) is currently trading at $2.88, reflecting a market capitalization of approximately $862.16 million. The company reports a negative net income of $211.82 million, resulting in a profit margin of 0.0% and a forward P/E ratio of -5.19, indicative of ongoing operational losses. As a pre-profitability biotechnology firm, SANA’s financial profile is characterized by significant cash burn rather than current earnings generation. Investors should note that the stock is trading near its 52-week low of $2.61, highlighting recent market pressure on the valuation.

### Recent Developments

Sana Biotechnology, Inc. has recently filed its 10-K annual report and 10-Q quarterly report, with filing dates of March 3, 2026, and August 10, 2026, respectively. These regulatory submissions highlight significant risk factors, particularly emphasizing how worsening global geopolitical and economic conditions could materially adversely affect the company. Investors should note that the company continues to operate with a net loss, reflecting the high-risk nature inherent in its biotechnology business model. Consequently, recent disclosures serve primarily as a reminder of the substantial uncertainties and financial challenges facing the firm rather than indicating positive operational milestones.

### SEC Filing Highlights
Sana Biotechnology faces substantial doubt regarding its ability to continue as a going concern, necessitating additional capital to sustain operations and avoid potential delays or elimination of product development programs. The company’s novel *ex vivo* and *in vivo* cell engineering platforms remain unproven, with no FDA-approved therapeutics derived from its pluripotent stem cell or fusogen technologies to date. Significant regulatory and safety challenges persist, including difficulties in creating appropriate models to evaluate product purity and the risk that regulatory authorities may not accept data explaining unexpected testing results. Furthermore, the company’s future growth is heavily dependent on retaining key personnel and successfully managing operational disruptions associated with scaling development and regulatory capabilities.

### Risk Factors

*   **Unproven Technology and Development Uncertainty:** The company’s novel ex vivo and in vivo cell engineering platforms are based on preliminary scientific evidence with substantial doubt regarding feasibility; preclinical results may not accurately predict human safety or efficacy, and product candidates may exhibit unexpected variability across different indications.
*   **Regulatory and Safety Challenges:** Significant hurdles exist in creating appropriate models to evaluate safety and purity, with a high risk that unexpected testing results may not be satisfactorily explained to regulators, potentially leading to delays or rejection of therapeutic approvals.
*   **Financial Viability and Commercialization Risks:** There is substantial doubt regarding the company’s ability to continue as a going concern due to the need for additional funding; failure to successfully develop, commercialize, or raise capital for its product candidates could materially adversely affect its business and force the elimination of development programs.

## Audited (Exec Summary + Outlook)

### Executive Summary
Sana Biotechnology, Inc. operates as a pre-profitability biotechnology firm leveraging novel *ex vivo* and *in vivo* cell engineering platforms, currently trading at $2.88 with a market capitalization of approximately $862.16 million. The stock is notable for its proximity to the 52-week low of $2.61 and its substantial operational losses, which have triggered going-concern doubts and highlight the intense financial pressure inherent in its high-risk business model. The single most important near-term variable shaping the outcome is the company’s ability to secure additional capital to sustain operations while navigating the significant regulatory and safety hurdles associated with its unproven therapeutic candidates.

### Outlook
The directional outlook for Sana Biotechnology remains cautiously cautious, dominated by the immediate imperative of capital preservation and the binary nature of its scientific validation. Key variables to monitor include the company’s progress in securing necessary funding to address going-concern doubts, the successful navigation of complex regulatory pathways for its cell engineering platforms, and the retention of critical scientific personnel. The thesis would strengthen if the company demonstrates clear milestones in proving the safety and efficacy of its *ex vivo* and *in vivo* technologies, thereby alleviating investor fears regarding unproven feasibility; conversely, any further delays in regulatory acceptance or failure to raise adequate capital would significantly weaken the investment case by increasing the risk of program elimination or insolvency.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "currently trading at $2.88"
LABEL: SUPPORTED
REASON: The raw source data explicitly lists `"current_price": 2.88`.

---

CLAIM: "market capitalization of approximately $862.16 million"
LABEL: SUPPORTED
REASON: The raw source data lists `"market_cap": 862158656.0`, which rounds to $862.16 million; the pre-written Financial Health section also states this figure explicitly.

---

CLAIM: "proximity to the 52-week low of $2.61"
LABEL: SUPPORTED
REASON: The raw source data explicitly lists `"week_52_low": 2.61`, and $2.88 is indeed close to (and above) that low, making the positional claim arithmetically valid.

---

CLAIM: "substantial operational losses"
LABEL: SUPPORTED
REASON: The raw source data lists `"net_income": -211822000.0` (a net loss of ~$211.82 million), confirming substantial operational losses.

---

CLAIM: "going-concern doubts"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights and RAG — Risk Factors sections both explicitly state "There is substantial doubt as to the company's ability to continue as a going concern," and this is echoed in the SEC Filing Highlights pre-written section.

---

**OUTLOOK**

The Outlook section contains no specific quantitative figures, price targets, thresholds, ratios, metrics, percentages, named product milestones, or forward-looking numbers. All claims in the Outlook are qualitative directional statements (e.g., "cautiously cautious," "binary nature," "key variables to monitor," "thesis would strengthen if") grounded in the qualitative risk disclosures present in the source data. There are no numerical claims to audit in this section.

---

**SUMMARY**

All quantitative claims in the Executive Summary are **SUPPORTED** by the raw source data. The Outlook section contains no quantitative or specifically enumerated forward-looking figures requiring audit entries.
